Physician profile

Brian D King

Family Medicine · Goshen, IN

NPI 1104896307

$1,192.10

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $217.31 2019-2021
Janssen Pharmaceuticals, INC $188.60 2019-2021
Novo Nordisk INC $100.22 2019-2021
Abbvie INC. $83.52 2021
Novartis Pharmaceuticals Corporation $83.08 2019
Pfizer INC. $63.98 2021
Astrazeneca Pharmaceuticals Lp $60.23 2020-2021
Glaxosmithkline, LLC. $49.96 2021
Abbott Laboratories $49.79 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $48.73 2021
Amgen INC. $35.41 2021
Bayer Healthcare Pharmaceuticals INC. $33.24 2021
Dexcom, INC. $28.54 2021
Ironshore Pharmaceuticals INC. $23.98 2019
Merck Sharp & Dohme LLC $22.85 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Sun Pharmaceutical Industries INC. $21.66 2020
Acadia Pharmaceuticals INC $17.89 2021
Insulet Corporation $17.23 2021
Eisai INC. $15.57 2020
Sanofi-Aventis U.S. LLC $15.49 2021
Takeda Pharmaceuticals U.S.A., INC. $14.82 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian D King

$1,192.10

in general payments reported 2019-2025

Years
2019-2022
Top company
Lilly USA, LLC

https://glasscript.com/doctor/321879/brian-d-king

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.